SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 57.58+0.9%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (10008)1/13/2004 10:23:12 PM
From: James Hutton  Read Replies (1) of 52153
 
BIomaven:

I've followed ADLR for a long time and was wondering if this might not be an opportunity to reenter. I've traded it a few times, but this appears as though it might be an opportunity for a longer term hold.

What do you mean by "underpowered?" My understanding was that the last trials did not have enough patients to provide statistically significant results, so ADLR did additional trials with more patients. Is this issue enough of a patient population, or that they can't get consistent statistically significant results as to effectiveness?

What did the press release mean that the 12 mg dose was not statistically significant because the 6 mg dose was not? I don't quite understand that.

Thanks for any light you can shed here.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News